drugset / Trial / NCT06584032
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The goal of this study is to evaluate whether fruquintinib(HMPL-013) plus sintilimab(IBI308) is safe and effective in the treatment of advanced endometrial cancer(EMC).
Timeline
- Start
- 2024-12-12
- Primary completion
- 2029-01-08
- Completion
- 2029-06-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Doxorubicin | Other / unclassified | 60 mg/m2 | Intravenous |
| Subject | Fruquintinib | Small molecule | — | Oral |
| Comparator | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |
| Subject | Sintilimab | Monoclonal antibody | — | Intravenous |